The nation of Zimbabwe has rejected a significant US health deal worth $367m (£272m) over five years because of the United States' insistence on sensitive biological samples.
This rejection became public following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
A government representative has since stated that the United States was requesting genetic material for research and commercial purposes but was not willing to share the benefits from future treatments.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further negotiations to find a agreement acceptable to both sides so the country's vital HIV programme can be sustained.
Broader Background
This development comes after a similar situation in Kenya, where a court blocked a similar deal with the US after legal challenges were filed about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and responsibility.
According to reports, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – like new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would supply the basic resources for medical research with no assurance that the resulting innovations would be accessible to our citizens should a new health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting systems already established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This system is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how subsequent co-operation might be structured in a manner that respects the independence and interests of both nations."
Medical Community Response
Medical experts said it recognised the government's concerns, but suggested that talks need to persist considering much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it said.
This impasse highlights the ongoing challenges between accepting vital foreign assistance and protecting national sovereignty in an increasingly interconnected world.